| Name | Title | Contact Details |
|---|
The new and innovated concept of DeliverIt Pharmacy came from our 20 years of experience. We have seen it all, the frustrations and hassles customers have to go through just to get their prescription. At DeliverIt Pharmacy we strive to keep the balance of affordable and convenience for our customers while performing proficiently and efficiently. We conveniently offer a variety of ways for you to get your prescription such as delivery, drive-thru, and walk-in pickup so there`s no frustrating long-lines to wait in. This will allow you to spend more time with your family, or return to your busy schedule of work or school! We offer compounding, which allows us to work with your physician to customized your prescription to your individual needs. We care for your love one`s well-being just as much as you do! Whether it`s your children, parents, or pets! We offer a variety of methods to make it easier for you to get them to comply with their medication
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
Watson Pharmaceuticals, Inc. is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.